CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

MUNICH–(BUSINESS WIRE)–CatalYm today announced the presentation of two preclinical data sets expanding the mechanistic understanding and clinical application of its lead anti-GDF-15 antibody candidate, visugromab, at the upcoming Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, USA. The findings will be presented in two poster sessions…
Click here to view original post